ONCOCYTE CORP's ticker is OCX and the CUSIP is 68235C107. A total of 60 filers reported holding ONCOCYTE CORP in Q4 2022. The put-call ratio across all filers is - and the average weighting 0.0%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q1 2023 | $73,600 | +10.4% | 207,675 | 0.0% | 0.06% | -1.8% |
| Q4 2022 | $66,643 | -83.8% | 207,675 | -63.1% | 0.06% | -83.9% |
| Q3 2022 | $411,000 | -20.7% | 563,350 | -2.2% | 0.35% | -13.4% |
| Q2 2022 | $518,000 | -39.8% | 575,750 | -0.4% | 0.41% | -26.8% |
| Q1 2022 | $861,000 | -31.4% | 578,150 | 0.0% | 0.56% | -26.1% |
| Q4 2021 | $1,255,000 | -38.9% | 578,150 | +0.2% | 0.76% | -40.8% |
| Q3 2021 | $2,055,000 | -15.1% | 577,200 | +36.9% | 1.28% | -12.0% |
| Q2 2021 | $2,421,000 | +10.1% | 421,775 | -0.5% | 1.45% | -8.3% |
| Q1 2021 | $2,199,000 | +117.1% | 423,775 | 0.0% | 1.58% | +102.9% |
| Q4 2020 | $1,013,000 | +217.6% | 423,775 | +84.7% | 0.78% | +181.6% |
| Q3 2020 | $319,000 | -22.6% | 229,425 | +6.4% | 0.28% | -31.6% |
| Q2 2020 | $412,000 | -22.1% | 215,625 | 0.0% | 0.40% | -40.2% |
| Q1 2020 | $529,000 | +32.9% | 215,625 | +21.9% | 0.68% | +74.5% |
| Q4 2019 | $398,000 | – | 176,878 | – | 0.39% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| BROADWOOD CAPITAL INC | 14,716,204 | $20,456,000 | 1.61% |
| PURA VIDA INVESTMENTS, LLC | 6,022,534 | $8,371,000 | 0.43% |
| P.A.W. CAPITAL CORP | 199,700 | $278,000 | 0.30% |
| Penbrook Management LLC | 229,425 | $319,000 | 0.28% |
| PERKINS CAPITAL MANAGEMENT INC | 39,725 | $55,000 | 0.05% |
| GSA CAPITAL PARTNERS LLP | 201,047 | $279,000 | 0.05% |
| Private Wealth Partners, LLC | 150,000 | $209,000 | 0.02% |
| Phoenix Holdings Ltd. | 317,138 | $426,000 | 0.02% |
| BRIDGEWAY CAPITAL MANAGEMENT, LLC | 255,300 | $355,000 | 0.01% |
| ETF MANAGERS GROUP, LLC | 157,933 | $226,000 | 0.01% |